Idioma:

Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients

Espinoza, Jaime A ; García, Patricia ; Bizama, Carolina ; Leal, José L ; Riquelme, Ismael ; Weber, Helga ; Macanas, Patricia ; Aguayo, Gloria ; Viñuela, Eduardo ; Roa, Juan C ; Nervi, Bruno

Histopathology, 2016-04, Vol.68 (5), p.722-728 [Periódico revisado por pares]

England: Blackwell Publishing Ltd

Texto completo disponível

Citações Citado por

Enviar para

Título:
Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients
Autor: Espinoza, Jaime A ; García, Patricia ; Bizama, Carolina ; Leal, José L ; Riquelme, Ismael ; Weber, Helga ; Macanas, Patricia ; Aguayo, Gloria ; Viñuela, Eduardo ; Roa, Juan C ; Nervi, Bruno
Assuntos: Adenocarcinoma - diagnosis ; Adenocarcinoma - drug therapy ; Adenocarcinoma - metabolism ; Aged ; Antimetabolites, Antineoplastic - therapeutic use ; Chemotherapy, Adjuvant ; Deoxycytidine - analogs & derivatives ; Deoxycytidine - therapeutic use ; ENT1 ; equilibrative nucleoside transporter 1 ; Equilibrative Nucleoside Transporter 1 - metabolism ; Female ; Gallbladder - diagnostic imaging ; Gallbladder - metabolism ; gallbladder cancer ; Gallbladder Neoplasms - diagnosis ; Gallbladder Neoplasms - drug therapy ; Gallbladder Neoplasms - metabolism ; gemcitabine ; Humans ; Immunohistochemistry ; Male ; Middle Aged ; SLC29A1 ; Survival Analysis
É parte de: Histopathology, 2016-04, Vol.68 (5), p.722-728
Notas: istex:D94D2B3D49AFDA49F82734DA99B0BFB70334610E
Millennium Institute on Immunology and Immunotherapy - No. BN-P07/088-F
FONDECYT Fondo Nacional de Investigación y Tecnología - No. JCR-1130204; No. PG-11130515; No. JAE-3140308; No. CA-3140426
ArticleID:HIS12805
FONDAP Fondo de Fomento al Desarrollo Científico y Tecnológico - No. JCR-15130011
ark:/67375/WNG-NZFW6T39-B
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Descrição: Aims Equilibrative nucleoside transporter 1 (ENT1) is the major transporter of the chemotherapeutic drug gemcitabine, the current therapy for advanced gallbladder cancer (GBC). ENT1 expression has been proposed as a predictive marker for gemcitabine‐treated pancreatic cancer patients. The aim of study was to explore the value of ENT1 measurement in chemotherapy‐naïve patients with advanced GBC. Materials and results Immunohistochemistry for ENT1 was performed on 214 GBC samples from patients who had never undergone co‐adjuvant or neo‐adjuvant chemotherapy. Advanced GBC cases were divided into groups with low or high ENT1 expression. Kaplan–Meier tests were used for survival analyses. The Cox regression method was used to assess the association of ENT1 expression with overall survival (OS). Low ENT1 expression was associated with younger patient age (P = 0.03) and moderate‐to‐poor histological differentiation (P = 0.01). pT2 patients with low ENT1 expression had shorter median survival (17.3 versus 28.7 months) and lower OS (17.3% versus 33.3%, P < 0.05) than patients with high ENT1 expression. Low ENT1 expression was an independent prognostic factor for OS (P = 0.036). Conclusions ENT1 is a prognostic marker for pT2 GBC patients. Additional studies are needed to determine whether ENT1 has predictive value for gemcitabine response in GBC.
Editor: England: Blackwell Publishing Ltd
Idioma: Inglês

Links

View this record in MEDLINE/PubMed

Voltar para lista de resultados

Realização: Logos de Redes Sociais:

Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients

Espinoza, Jaime A ; García, Patricia ; Bizama, Carolina ; Leal, José L ; Riquelme, Ismael ; Weber, Helga ; Macanas, Patricia ; Aguayo, Gloria ; Viñuela, Eduardo ; Roa, Juan C ; Nervi, Bruno

England: Blackwell Publishing Ltd

Buscando em bases de dados remotas. Favor aguardar.